首页> 外文学位 >Identifying and Targeting Cellular Mechanisms to Enhance Cisplatin Chemotherapeutic Response in Cancer.
【24h】

Identifying and Targeting Cellular Mechanisms to Enhance Cisplatin Chemotherapeutic Response in Cancer.

机译:鉴定和靶向增强癌症中顺铂化学治疗反应的细胞机制。

获取原文
获取原文并翻译 | 示例

摘要

Cisplatin is one of the most effective and widely used anticancer agents used especially in treating testicular, ovarian, head and neck and lung cancers. As in the case of many chemotherapeutic drugs, a clinical limitation is cancer recurrence and resistance. Cisplatin targets DNA and forms distinct lesions which block DNA replication and transcription. These lesions mediate the cisplatin cytotoxic response and their repair is detrimental to drug cytotoxicity. Cancers exhibit altered repair of cisplatin-DNA lesions leading to drug resistance. Thus, targeting the DNA repair mechanisms is important for increasing cisplatin efficacy. This study validates XPF/ERCC1, a DNA repair enzyme complex, as an important molecular target to enhance cisplatin sensitivity in cancer cells globally. XPF/ERCC1 is vital to the repair of all forms of cisplatin-DNA damage and hence important in mediating clinical response to cisplatin. XPF/ERCC1 enhances cisplatin cytotoxicity by inhibiting the repair of DNA damage. Our studies next identify small molecules that inhibit XPF/ERCC1 in primary and secondary in vitro screens. These compounds potentiate cisplatin sensitivity in cancer cells by inhibiting the repair of cisplatin-DNA damage. Further studies with these compounds could yield inhibitors which can clinically potentiate the effects of cisplatin and result in lower doses of cisplatin being administered while enhancing the cytotoxic effect. Our studies also identify gap junctions and their mediated intercellular communication as an important mechanism in maintaining cisplatin sensitivity. We show that gap junctional intercellular communication induces a bystander effect after cisplatin treatment in untreated bystander cells and hence further potentiates cisplatin's effect. The bystander effect elicits as DNA Double Strand Breaks (DSBs) and further sensitizes XPF/ERCC1 knockdown cells to cisplatin. Further studies might help identify the "signal" that induces DSBs in bystander cells and how unrepaired DNA damage enhances the bystander effect. Studies delineating mechanisms that mediate resistance or maintain sensitivity are important in improving platinum-based therapeutics.
机译:顺铂是最有效和广泛使用的抗癌药之一,尤其用于治疗睾丸癌,卵巢癌,头颈癌和肺癌。与许多化疗药物一样,临床局限性是癌症的复发和耐药性。顺铂靶向DNA并形成独特的损伤,从而阻止DNA复制和转录。这些损伤介导顺铂的细胞毒性反应,其修复对药物细胞毒性有害。癌症表现出顺铂DNA损伤修复的改变,从而导致了耐药性。因此,靶向DNA修复机制对于提高顺铂疗效非常重要。这项研究证实,DNA修复酶复合物XPF / ERCC1是增强全球癌细胞中顺铂敏感性的重要分子靶标。 XPF / ERCC1对修复各种形式的顺铂DNA损伤至关重要,因此在介导对顺铂的临床反应中也很重要。 XPF / ERCC1通过抑制DNA损伤的修复增强顺铂的细胞毒性。接下来,我们的研究确定了在初级和次级体外筛选中抑制XPF / ERCC1的小分子。这些化合物通过抑制顺铂DNA损伤的修复增强了癌细胞对顺铂的敏感性。这些化合物的进一步研究可能会产生抑制剂,这些抑制剂可在临床上增强顺铂的作用,并导致在增强细胞毒性作用的同时降低顺铂的剂量。我们的研究还确定了间隙连接及其介导的细胞间通讯是维持顺铂敏感性的重要机制。我们显示间隙连接细胞间通讯诱导顺铂治疗未处理的旁观者细胞后的旁观者效应,因此进一步加强顺铂的效应。旁观者效应会引起DNA双链断裂(DSB),并进一步使XPF / ERCC1敲低细胞对顺铂敏感。进一步的研究可能有助于确定在旁观者细胞中诱导DSB的“信号”,以及未修复的DNA损伤如何增强旁观者的作用。描述介导抗药性或维持敏感性的机制的研究对于改善铂基治疗剂很重要。

著录项

  • 作者

    Arora, Sanjeevani.;

  • 作者单位

    The University of Toledo.;

  • 授予单位 The University of Toledo.;
  • 学科 Biology Molecular.;Health Sciences Oncology.;Chemistry Biochemistry.
  • 学位 Ph.D.
  • 年度 2012
  • 页码 232 p.
  • 总页数 232
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号